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Abstract: Differential alteration of Toll-like receptor (TLR)
expression in inﬂammatory bowel disease (IBD) was ﬁrst
described 10 years ago. Since then, studies from many groups
have led to the current concept that TLRs represent key mediators
of innate host defense in the intestine, involved in maintaining
mucosal as well as commensal homeostasis. Recent ﬁndings in
diverse murine models of colitis have helped to reveal the mecha-
nistic importance of TLR dysfunction in IBD pathogenesis. It has
become evident that environment, genetics, and host immunity
form a multidimensional and highly interactive regulatory triad
that controls TLR function in the intestinal mucosa. Imbalanced
relationships within this triad may promote aberrant TLR signal-
ing, critically contributing to acute and chronic intestinal inﬂam-
matory processes in IBD colitis and associated cancer.
(Inﬂamm Bowel Dis 2010;16:1583–1597)
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P
erturbed homeostasis between commensal bacteria and
mucosal immunity serves as a critical determinant in the
development of gut inﬂammation in inﬂammatory bowel
disease (IBD) in the genetically susceptible individual.
1,2
Innate immune cells must exert a rigorous process of rapid
and precise discrimination between ‘‘self’’ and ‘‘nonself’’
based on the recognition of broadly conserved molecular
patterns by so-called pattern recognition receptors (PRRs).
3
Toll-like receptors (TLRs), a class of transmembrane PRRs,
play a key role in induction of pro/antiinﬂammatory genes
and control of adaptive immune responses.
4,5 In 2000, dif-
ferential modulation of TLRs in the intestinal mucosa was
ﬁrst described in IBD.
6 Since then, much progress has been
made in deﬁning the cell-speciﬁc effects and mechanisms
through which TLRs mediate recognition and sorting of the
broad spectrum of diverse products of the luminal micro-
biota and how aberrant TLR modulation may contribute to
the development of IBD. This review focuses on recent
advances in our understanding of the complex involvement
of regulatory effects (environmental factors, gene variants,
and mucosal immunity) on intestinal TLR function in IBD
pathogenesis (Fig. 1). Within a healthy host, TLR signaling
drives basal immune mechanisms essential for protecting
host barrier integrity and maintaining commensal composi-
tion and tolerance. However, within a susceptible individual,
aberrant or dysfunctional TLR signaling may impair com-
mensal-mucosal homeostasis, thus contributing to ampliﬁca-
tion and perpetuation of tissue injury and consequently
leading to chronic inﬂammation in IBD.
STRUCTURE AND SIGNALING
TLRs comprise a class of 13 mammalian type I trans-
membrane glycoproteins (10 in humans and 12 in mice)
which all contain multiple leucine-rich repeat motifs (LRR)
in the large, divergent ectodomain and a highly conserved
region in the short intracellular tail, called the Toll-inter-
leukin-1 receptor (TIR) domain. The TIR domain consists
of sites essential for interaction between homo- or heterodi-
meric TLR subunits as well as recruitment of cytoplasmic
adapter proteins to initiate downstream signaling cascades.
The TIR domain is not unique to TLRs and can also be
found in receptors of the IL-1, IL-18, and IL-33 families,
implying evolutionary convergence into common immune
responses to distinct inﬂammatory stimuli.
TLRs recognize alarm signals that can be classiﬁed
into microbiota-/viral-associated (commensal/pathogen) and
damage-associated (endogenous/exogenous) molecular
patterns. Molecular signatures of different classes of micro-
organisms or features include, e.g., lipopeptides: TLR2;
viral-derived dsRNA: TLR3; lipopolysaccharide: TLR4;
ﬂagellin: TLR5 and CpG DNA: TLR9. Ligand binding
elicits receptor activation through conformational changes.
To date, at least ﬁve different adaptor proteins have been
identiﬁed: MyD88, Mal/TIRAP, TRIF/TICAM-1, TRAM/
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signal through the adaptor protein MyD88, while TLR4
uses both MyD88-dependent and MyD88-independent path-
ways. Engagement of MyD88 activates a series of signal-
ing modules, including IRAK, TRAF6, and TAK1, ulti-
mately leading to activation of transcription factors (NF-
jB, AP-1, Elk-1, CREB, STATs, or IRF) (reviewed, e.g.,
in Refs. 7,8). Besides MyD88, TRAF6 functions down-
stream as another common signaling checkpoint of several
pathways and thus interconnects the IL-1R/TLR and TNFR
superfamilies. Subsequent transcriptional activation of
unique and common TLR target genes encoding pro- and
antiinﬂammatory cytokines and chemokines as well as the
induction of costimulatory molecules control the activation
of antigen-speciﬁc and nonspeciﬁc adaptive immune
responses by lamina propria cells. All of these various
downstream effects are critically involved in protection of
host homeostasis through control of milieu inﬂuences.
EXPRESSION PATTERN IN HEALTH AND IBD
TLRs are inducibly or constitutively expressed in dif-
ferent combinations throughout the whole gastrointestinal
tract by a wide variety of cell types, including the four








various professional immune cell subsets within the intesti-
nal lamina propria (such as monocytes/macrophages,
22,23
dendritic cells [DCs],
24–26 and CD4þ T cells
27,28). Speciﬁc
cell types express individual patterns of TLRs at different
anatomical sites. For instance, when differentiating into
immature DCs, monocytes progressively lose the expres-
sion of some TLRs, but gain the expression of others.
29
Bone-marrow-derived CD11cþ DC express substantial lev-
els of TLR4 to rapidly recognize detrimental pathogenic
threats.
30 In contrast, lamina propria CD11cþ DCs do not
express TLR4 to maintain hyporesponsiveness to omnipre-
sent lipopolysaccharide (LPS) in the gut lumen.
25,26 Dis-
tinct TLR expression patterns may thus reﬂect different
functional necessities of TLR ligand recognition at differ-
ent strategic locations.
Based on the optimal sites of ligand recognition and
binding, TLRs are strategically localized either on the cell
surface (TLR1/2/4/5/6) or in intracellular compartments
(TLR3/7/8/9). Intestinal epithelial TLR localization and





TLR2 and TLR4 are preferentially localized at the apical
pole of differentiated enterocytes in vitro,
33 TLR5 is stably
expressed at the basolateral pole of the intestinal epithelium
in vitro,
11 the major site of action for Salmonella-translo-
cated ﬂagellin upon injury. Although the presence of MD-2
retains TLR4 to the cellular surface localization,
34 TLR4 is
capable to shuttle its cargo LPS between plasma membrane
and endosomal structures,
33 which are part of the Golgi ap-
paratus.
35,36 In addition, distinct TLRs may interact with the
endoplasmatic reticulum (ER) through accessory molecules,
such as TLR3/7/9 via Unc93B,
37 TLR1/4 via PRAT4A,
38 or
TLR4/9 via heat shock protein 96.
39
In the normal intestine, TLR2 and TLR4 are present
only in small amounts on IEC and lamina propria mononu-
clear cells (LPMNCs) in vivo, minimizing recognition of
the environment and maintaining a basal state of activa-
tion.
6,10,12–14,23 TLR inhibition acts to avoid inappropriate
activation despite the omnipresent microbiota. Cellular
mechanisms, like compartmentalization or differential acti-
vation, as well as several negative regulators, have been
found to attenuate or abrogate TLR activation in the intes-
tinal mucosa. Once host threats are encountered, these in-
hibitory mechanisms can be switched off, and positive reg-
ulators allow TLR signaling to elicit important immune
responses, in the attempt to eliminate the danger. But sus-
tained TLR hyperactivation may provoke chronic inﬂam-
mation in IBD. TLR4 is signiﬁcantly increased in primary
IEC and LPMNC throughout the lower gastrointestinal tract
in active disease of both human Crohn’s disease (CD) and
ulcerative colitis (UC),
6 maximizing responsiveness to the
environment and reﬂecting an aberrant state of activation.
TLR4 signaling requires three accessory molecules,
CD14, LBP, and MD-2. Under healthy conditions, expression
of this receptor complex is generally low in the intestinal mu-
cosa,
22,31,40,41 but signiﬁcantly upregulated in various cell sub-
sets in either nonactive and/or active human IBD colitis.
40–42
MD-2/TLR4 upregulation could also result from ligands other
than abundant LPS. T-cell-derived cytokines, such as
FIGURE 1. Environment, genetics, and host immunity form
a multidimensional and highly interactive regulatory triad
that controls TLR function in the intestinal mucosa. Multiple
factors may positively or negatively regulate TLR signaling.
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1584interferon gamma (IFNc) and tumor necrosis factor alpha
(TNF-a), which play signiﬁcant pathophysiological roles in
triggering IBD, have been found to upregulate intestinal epi-
thelial TLR4 expression in vitro.
31,43 Changes in the commen-
sal composition in the genetically susceptible host may result
in aberrant TLR4 hyperresponsiveness of the intestinal mu-
cosa.
44 But receptor upregulation may also reﬂect functional
loss of immune responses.
ENVIRONMENT
Commensals
Commensal–host interactions are based on symbiotic
mutualism in which both partners beneﬁt. The constant ex-
posure of the intestinal mucosal surface to commensal-
derived TLR ligands induces a basal state of activation of
downstream signaling pathways that ensures mucosal ho-
meostasis through limited inﬂammatory responses and
accelerated restitution and healing in the healthy intestine.
Commensal composition and tolerance represent essential
mechanisms of maintaining hyporesponsiveness of the
intestinal immune system.
The composition of the commensal microbiota
depends on host immunity, genetics, and environment.
Host immunity contains the commensal composition to
avoid excessive antigen signals. Emerging evidence reveals
that host-derived antimicrobial peptides, predominantly
Paneth cell a-defensins, have a key role in determining the
commensal composition.
45 In this function, innate immu-
nity is essentially complemented by adaptive immune
mechanisms. Bacterial overgrowth and mucosal penetration




Foxp3þ) T regulatory (Tregs) critically coordinate cellular
IgA responses in the intestinal mucosa.
48 TLR stimulation
of IEC may induce active DC sampling
49 and production
of APRIL in neighboring DCs, which then stimulate naive
IgDþ B cells to express mucosa-protective IgA2 in the
presence of IL-10.
47 TLR ligation of IEC may also pro-
mote IgG and IgA class switching via BAFF, which is self-
controlled through SLPI.
50 In TLR deﬁciency, adaptive im-
munity (and/or other PRRs) can step into the breach and
restore effective bacterial clearance by high production of
commensal-speciﬁc IgG antibodies.
51
In return, the composition of the commensal micro-
biota actively shapes mucosal and systemic immune home-
ostasis of the host at multidimensional levels. The presence
of commensals modulates TLR expression in the intestinal
mucosa.
52 The complexity of the commensal composition
is critical in augmenting protective mucosal immunity.
53
Certain commensal species help to maintain an immunore-
gulatory environment through antiinﬂammatory effects and
inhibition of speciﬁc intracellular signal transduction path-
ways in the intestinal mucosa.
54,55 Several studies have
recently demonstrated the importance of the commensal
composition in orchestrating the TH17$Treg balance
within the lamina propria.
56–58 Any disturbance in this
ﬁne-tuned partnership between commensals and the host
cells may impair their mutually beneﬁcial interactions.
Distinct perturbations and alterations in the commensal
composition may deregulate mucosal immune responses.
However, in the genetically immunoincompetent host, the
commensal composition may shift and turn pathogenic.
Aberrant expansion of selected commensals
59 may launch
tissue-destructive host responses and drive colitis.
60
Changes in the commensal composition may differen-
tially modulate mucosal TLR responsiveness, thus subvert-
ing immune responses to a predominantly proinﬂammatory
phenotype. IBD patients contain abnormal compositions of
the intestinal microbiota, characterized by reduced bacterial
diversity,
61 temporal instability,
62 and depletion of distinct
commensal species (members of the phyla Firmicutes and
Bacteroidetes).
63 The latter includes a lower proportion of
Faecalibacterium prausnitzii, an antiinﬂammatory com-
mensal that counterbalances dysbiosis.
64 CD patients are
predisposed to become colonized with facultative-patho-
genic commensals, such as the adherent invasive E. coli
(AIEC) that harbors various virulence factors involved in
adhesion and invasion of the IEC barrier.
65 Chitinase
3-like-1 may play an important pathogenic role in media-
ting enhancement of commensal adhesion to IEC in IBD.
66
Oral infection of mice with ﬂagellated AIEC
67 induces a
signiﬁcant increase of TLR5 expression in the gut that is
associated with colitis aggravation.
68 Host defense mecha-
nisms, especially antimicrobial activities through defensins
that limit bacterial invasion and expansion, are severely
impaired in IBD. Decreased expression of Paneth cell
a-defensins has recently been associated with increased
susceptibility to develop CD ileitis.
69 MyD88-dependent
signaling, presumably via TLR2/4,
19,70,71 is crucial for lim-
iting mucosal adherence and penetration of commensals
through production of Paneth cell a-defensins
16 and
RegIIIc.
72,73 Several causal scenarios are plausible in IBD
pathogenesis, but remain to be directly proven: Genetic
defects and/or aberrant immune-mediated modulation of
speciﬁc TLRs may diminish antimicrobial activities and
disturb bacterial clearance, leading to a colitogenic com-
mensal composition. Changes in the commensal composi-
tion may subvert the mucosal innate immune system, lead-
ing to TLR-mediated hyper- or hyporeactive immune
responses. Dysbiosis may allow facultative-pathogens to
submerse, avoiding effective TLR recognition and bacteri-
cidal activation. Taken together, it will be important to
deﬁne the mechanisms in detail: 1) how TLR signaling
shapes the antimicrobial tone of the intestinal immune sys-
tem, in this way critically inﬂuencing the commensal
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1585composition, and 2) how IBD-related changes in the com-
mensal composition and facultative-pathogenic commensals
may functionally skew TLR signaling in the genetically
susceptible host.
Several negative control mechanisms that ensure tol-
erance to abundant resident microbiota and regulated acti-
vation via TLRs in the intestinal mucosa have recently
been described (detailed review in Ref. 74): decreased sur-
face receptor expression which limits frontline recogni-
tion,
6,10,41,43 high expression levels of the downstream sig-
naling suppressor Tollip, which inhibits IRAK activation,
13
ligand-induced activation of PPARc (peroxisome prolifera-
tor-activated receptor c), which uncouples NF-jB-depend-
ent target genes in a negative feedback loop,
55,75 negative
regulation of proinﬂammatory IL-1R/TLR4 signaling
through SIGIRR (single immunoglobulin IL-1R-related
molecule; also known as TIR8), which abolishes exagger-
ated immune responses to commensal bacteria in colitis,
76–78
ubiquitylation of key TLR signaling components via ubiq-
uitin-editing enzymes, such as A20,
79–81 or E3 ubiquitin-
protein ligases, such as TRIAD3A,
82 and selective induc-
tion of transcriptional repressors, such as Bcl-3, which
limits proinﬂammatory responses via NF-jB.
83 Digestive
enzymes, such as intestinal alkaline phosphatase
84 or tryp-
sin,
41 may alter TLR ligand recognition. Cytokines, e.g.,
IL-4 or IL-13, may also suppress TLR-mediated signaling
pathways.
85 Commensal intolerance, i.e., exaggerated
immune responsiveness of TLRs toward commensals, may
occur as a consequence of endogenously or exogenously
induced disturbance of any TLR-dependent signaling
mechanisms of commensal tolerance. Positive regulators
may enhance proinﬂammatory TLR signaling via NF-jB,
such as the scaffold protein AKAP13.
86 Inﬂammation in
IBD may result from persistent commensal intolerance
because of altered pattern recognition and TLR signaling.
However, a more comprehensive analysis of the diverse
TLR-dependent signaling mechanisms of commensal-
mediated suppression of intestinal inﬂammation and how
imbalance in positive versus negative signaling regulators
may contribute to the pathogenesis of human IBD is
needed.
Pathogens
Episodes of Salmonella/Campylobacter gastroenteritis
have been associated with increased risk of developing
IBD.
87 ‘‘Loss-of-function’’ mutations in the TLR4 gene can
predispose to these Gram-negative bacteria and increase sus-
ceptibility to enteric infection—which may represent an
essential disease trigger in IBD pathogenesis. Pathogenic
infections may change the commensal composition and dis-
rupt commensal tolerance. Campylobacter jejuni may
directly promote the internalization and translocation of
commensal bacteria.
88 Host deﬁciency in bacterial clearance
may allow conventional or opportunistic pathogens to pro-
voke and sustain inﬂammatory responses via TLRs (and
other PRRs), exacerbating or complicating underlying IBD,
which may explain the high prevalence of persistent or recur-
rent infections in patients with chronic IBD.
89 Viral patho-
gens, such as cytomegalovirus (CMV; a known risk factor in
refractory and complicated IBD
90), may also manipulate
TLR-mediated immunity by priming TH1/TH17-dependent
immune responses to the commensal microbiota.
91 Inﬂam-
matory damage may be augmented by exaggerated maladap-
tive TLR responses through infection with attaching/effacing
pathogens, as shown for the murine pathogen Citrobacter
rodentium.
92 Certain pathogenic microbes appear to have the
capacity not only to avoid, but directly interfere with signal-
ing components of the innate immune system, thereby sub-
verting host defense mechanisms for their own virulent pur-
poses (reviewed in Ref. 93). Identiﬁcation of subversion
mechanisms that result in or from aberrant innate immunity
of the intestinal mucosa may help to understand the differen-
tial inﬂuences of distinct (facultative/obligate) pathogens in
IBD pathophysiology.
Exogenous Injury Signals
Any mucosal insult of the intestine may result in tissue
damage and activation of the innate and adaptive immune
systems, followed by cell recruitment, proliferation, and
migration, ultimately leading to wound healing. Deﬁcient
TLR signaling may imbalance commensal-dependent home-
ostasis, facilitating injury and leading to inﬂammatory
disease. Dextran sulfate sodium (DSS)-induced colitis repre-
sents a well-established ‘‘damage’’-model of acute chemi-
cally induced toxic injury in crypt colonic epithelial cells ini-
tiating inﬂammatory responses in the lamina propria. Injury
may allow luminal TLR ligands to access the lamina propria
and recruited primary immune cells to respond strongly to
these ligands, thus triggering tissue destruction. Mice deﬁ-
cient in TLR2/3/4/5/9 or MyD88 exhibit delayed or dimin-
ished tissue repair responses during acute DSS-induced
intestinal damage.
94–99 Accordingly, systemic administration
of a TLR4-blocking antibody impairs restoration of tissue in-
tegrity during DSS-colitis, despite limiting exaggeration of
acute inﬂammatory responses induced by recruited cells.
100
Several recent studies suggest that TLR signaling exerts
many important cytoprotective functions in the intestinal epi-
thelium (and adjacent cell subsets) which are required for
barrier preservation, cell survival and stability, and restitu-
tion, including, e.g., inhibition of apoptosis, migration, and
proliferation.
TLR2 is the only TLR identiﬁed so far to be capable
of directly modulating the complex network of closely
arranged tight (TJ) and gap junctions (GJ) of the intestinal
epithelium. We have previously shown that stimulation of
TLR2 rapidly enhances transepithelial resistance of the IEC
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TJ component.
101 ZO-1 binds to the key gap junctional pro-
tein connexin-43 (Cx43), thus enhancing assembly and stabi-
lization of gap junctional intercellular communication
(GJIC)—an essential mechanism for cellular and tissue ho-
meostasis. GJIC coordinates cell–cell passage of ions and
small metabolites, regulating cell proliferation, migration,
and differentiation (<1 kDa). In subsequent studies we dem-
onstrated that inﬂammatory stress induces early and com-
plete TJ/GJ-loss of the IEC barrier in the absence of TLR2,
which is not evident in the presence of TLR2.
97,102 Treat-
ment with the TLR2 ligand PCSK protects TJ/GJ-associated
integrity and decreases intestinal permeability, leading to
signiﬁcant amelioration of all clinical signs in acute DSS-
induced colonic inﬂammation during the recovery phase.
97
IEC-speciﬁc deﬁciency of Cx43 by mucosal RNA interfer-
ence leads to abrogation of TLR2-mediated IEC restitution
and delays wound closure in acute inﬂammatory stress-
induced injury in the intestine.
102 Collectively, these data
show that TLR2 protects the local mucosa by preservation of
TJ/GJ-associated architecture and GJIC between juxtaposed
IEC during acute intestinal damage.
The PI3K/Akt-pathway controls cell survival, which
plays a critical role in maintaining mucosal homeostasis.
Stimulation with TLR2/5 ligands induces signiﬁcant phos-
phorylation of Akt and its downstream substrates via
MyD88 in IEC, thus essentially limiting proinﬂammatory
stress signaling through the p42/p44 Mapk/p38 path-
ways.
97,103,104 As a result, absence of TLR2/5 leads to deﬁ-
cient antiapoptotic IEC protection against toxic DSS-medi-
ated damage,
97,99 which further compromises TJ-associated
barrier integrity and perpetuates intestinal inﬂammation. A
different antiapoptotic pathway has recently been deﬁned
for epithelial TLR4 and TLR9 activation, upregulating
expression of Cox-2,
105,106 which is known to suppress
apoptosis through PGE2 production in the gastrointestinal
tract. TLR4-mediated production of hyaluronic acid may
also induce macrophage Cox-2 and thus exert antiinﬂam-
matory effects during DSS colitis.
107 Mesenchyme-derived
PGE2 preserves proliferation of crypt progenitor cells via
MyD88, which is essential for IEC restitution during acute
DSS injury.
108 Of note, it was recently proposed that DSS
may act as a direct alarmin for TLR4,
107 but whether DSS
truly binds to TLR4 remains to be determined.
We have previously identiﬁed another, so far unap-
preciated, commensal-mediated antiapoptotic mechanism in
the intestinal mucosa.
17 Goblet cell (GC)-derived trefoil
factor 3 (TFF3) plays a major role in wound healing and
barrier repair of the intestinal mucosa.
109 We showed that
TLR2 acts to control terminal GC differentiation by selec-
tively regulating TFF3 expression in the colon, thus confer-
ring antiapoptotic protection of the intestinal mucosa
against acute inﬂammatory stress-induced damage. TLR2
deﬁciency results in an innate immune defect of GC-
derived TFF3, contributing to exacerbation of mucosal apo-
ptosis and associated leukocyte inﬂux during acute DSS
injury, which can be reversed by supplementation with
recombinant TFF3 peptide.
17 Taken together, several TLR-
dependent mechanisms that enhance IEC wound healing
(barrier integrity, survival, cell–cell communication, prolif-
eration, and migration) during acute exogenously induced
mucosal injury have functionally linked products of com-
mensal bacteria to innate immune protection of the
intestine.
Endogenous Danger Signals
Endogenous mediators and ligands may modulate
TLR responsiveness and induce aberrant activation of
TLRs under pathophysiological conditions. During tissue
injury and inﬂammation, impaired ‘‘self’’ versus ‘‘nonself’’
discrimination by aberrant TLRs may lead to self-directed
immune responses in autodysregulatory loops. For instance,
the ‘‘alarmin’’ HMGB1, which is actively secreted by
immune cells and passively released by necrotic nonim-
mune cells during colonic injury,
110 can aggravate proin-
ﬂammatory responses through activation of multiple
TLRs.
111 Excessive TLR activity may induce proapoptotic
signaling pathways in primary immune cells. Apoptotic sig-
nals, in combination with TLR engagement, may perpetu-
ate an innate IL-17 response,
112 thus contributing to further
tissue damage in IBD. However, development of TH17
polarization does not entirely depend on TLR signaling, as
it was recently shown that ATP, a potent stimulus for
NOD-like receptor (NLR)P3 inﬂammasome, triggers com-
mensal-mediated TH17 responses in MyD88/TRIF-deﬁcient
mice.
113 These ﬁndings highlight the complexity and diver-
sity of innate immunity in the intestinal mucosa, which
involves not only TLRs.
Danger signals can induce imbalances of intracellular
homeostasis. Such disturbances may cause accumulation of
unfolded proteins in the ER lumen, leading to an evolutio-
narily conserved cell stress response which, if not resolved,
triggers cell death. Severe or prolonged ER stress has been
implicated in initiation and/or perpetuation of intestinal
inﬂammation and may represent a primary or secondary
factor in the pathogenesis of IBD.
114–116 The close proxim-
ity to the ER makes the TLR apparatus especially vulnera-
ble to subcellular imbalances caused by pathophysiological
levels of ER stress and aberrant activation of the unfolded
protein response during chronic intestinal inﬂammation. In-
testinal epithelial ER dysfunction as a primary defect or
secondary to the inﬂammatory milieu may lead to misfold-
ing and retention of newly synthesized TLRs and associ-
ated coreceptors that critically rely on this protein quality
control machinery, as previously shown for MD-2 glyco-
protein.
41 Aberrant TLR/MD-2 accumulation in the ER
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1587could provide a means for limiting host reactivity by damp-
ening ligand responsiveness. Conversely, IEC disequilibrium
based on ER stress may turn other TLRs overly reactive to
the resident microbiota (such as TLR5),
116 which may exac-
erbate colitis. However, TLRs are also capable of initiating
distinct cell survival mechanisms to protect against exagger-
ated ER stress. For instance, the continuous presence of the
TLR4 ligand LPS may result in a state of ER hyporespon-
siveness by suppressing the proapoptotic C/EBP homologous
transcription factor (CHOP),
117 thus decreasing cellular sen-
sitivity to cytotoxic stress, e.g., in DSS-induced acute colitis,
as outlined above.
118 On the other hand, deﬁciency in TLR4
may reciprocally promote conditions of direct or indirect ER
stress
119 which may contribute to aggravation of colitis.
Emerging evidence points to autophagy as a fundamental
component of the innate immune process of cell survival
against ER stress. The importance of deregulated autophagy
in IBD pathogenesis has recently been elucidated by the
association of genetic variants in ATG16L1 and IRGM with
increased susceptibility to CD.
120–122 Upon detection of non-
self ligands, distinct TLRs may induce the autophagy ma-
chinery.
123 Conversely, autophagy may transfer TLR ago-
nists to the lysosomal pathway, thereby allowing recognition
by endosomal TLRs.
124 However, direct functional evidence
is lacking that TLR ligands may modulate autophagy in the
intestinal mucosa. Future studies are needed to dissect the
precise molecular mechanisms of cause and effect that dif-
ferentially inﬂuence the complex interdependence between
ER stress and TLRs in the healthy versus inﬂamed intestinal
mucosa in IBD. It must be clariﬁed whether defects in the
TLR pathways contribute to autophagic deﬁciency in IBD,
or vice versa, thus promoting intestinal disease through
impaired bacterial clearance and prolonged immune activa-
tion due to ER stress.
Food Antigens
Shifts in the commensal composition may increase
the ability of the microbiota to break down indigestible
ﬁber into short-chain fatty acids,
125 which may modulate
innate immunity by downregulating TLR4 in IEC.
126 High
oral iron supplementation aggravates acute DSS colitis,
127
presumably through aberrant induction of the TLR4-TRIF
pathway in LPMNC, resulting in enhanced LPS-mediated
proinﬂammatory cytokine expression.
128 More studies will
need to systematically determine the implications of differ-
ent dietary antigens on mucosal TLR regulation and func-
tion with the goal of gaining insight into the mechanisms
how these pleiotropic (co-)factors may possibly affect ini-
tiation, persistence, and relapses in human IBD.
GENETICS
Genetic variations in TLRs may alter host–commen-
sal interactions. A defect in TLRs may inﬂuence ligand
recognition, mucosal immune tolerance, and commensal
composition, leading to innate/adaptive immune hypo- or
hyperreactivity. Several studies have evaluated the func-
tional impact of TLR polymorphisms in IBD susceptibility
and/or progression. None of these relatively rare TLR var-
iants were captured as ‘‘major hits’’ by the recent genome-
wide association scans. Individual TLR variants may have
greater impact in terms of explaining differences in pheno-
type severity rather than providing predictions of disease
risk in IBD.
TLR1/2/4/5/6/9
A number of risk variants in the TLR1/2/6 genes
have been associated with distinct disease phenotypes of
IBD. UC patients with the polymorphisms TLR1-R80T and
TLR2-R753Q appear to exhibit increased risk to develop
pancolitis.
129 The TLR2-R753Q mediates IEC dysfunction,
failing to induce TFF3 synthesis in goblet cells
17 and inhib-
iting GJIC through loss of Cx43 in enterocytes,
102 which
impairs restitution during wound healing. Thus, the TLR2-
R753Q leads to more extensive disease due to impaired
innate immune host defense in a subgroup of IBD. The cel-
lular mechanistics of TLR1-R80T remains to be function-
ally deﬁned. The single nucleotide polymorphism within
TLR6, S249P, was associated with a slightly decreased
incidence of proctitis in IBD.
129
The TLR4 gene is localized on chromosome
9 (q32-33),
130 a genomic region in which a CD sus-
ceptibility gene has been implicated.
131 In active IBD, vari-
ant alleles in the TLR4 gene could induce functional dysre-
gulation of the LPS receptor. ‘‘Gain-of-function’’ mutations
could functionally exhibit proinﬂammatory effects in
response to physiological concentrations of LPS. Two com-
mon mutations in the human TLR4 gene, D299G and
T399I, have been observed to occur at a general frequency
of between 6% and 10% in Caucasian populations.
132
D299G polymorphism has been associated with CD as well
as UC in several populations
133–135; however, population
studies reveal differences in geographical distribution.
136
Increased susceptibility to IBD has been associated with
the coexistence of TLR4 and/or caspase recruitment do-
main 15 (CARD15) and BPI
137 mutated alleles.
138 The
presence of the D299G polymorphism in the absence of
CARD15 mutations seems to be a particularly strong pre-
dictor of a stricturing disease phenotype in CD patients.
139
Although D299G mutation (but not the T399I mutation)
has been shown to interrupt TLR4-mediated LPS signaling
in vitro,
140 which could result from conformational
changes,
141 the functional phenotypic consequences remain
unresolved in distinct cell types within the intestinal mu-
cosa and in IBD. Highly variable TLR4 gene mutations
have been identiﬁed in various mice strains that exhibit a
broad distribution of different phenotypic responses to
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142 suggesting
that additional gene–gene interactions are involved.
It is possible that the D299G mutation may induce
signaling disequilibrium of TLR5 leading to intestinal
inﬂammation through ‘‘over’’-recognition of ﬂagellin.
Hyperreactivity to ﬂagellins was observed in sera from
patients with CD.
67,143,144 A recently identiﬁed dominant-
negative TLR5 polymorphism (TLR5-stop), which leads to
75% loss of TLR5 function, reduces adaptive immune
responses to ﬂagellin, and, in Jewish cohorts, protects
against the development of CD.
145 Conversely, complete
loss of TLR5 in mice may result in the development of
spontaneous colitis via aberrant TLR4 signaling in response
to changes in the commensal composition.
44
The single-nucleotide polymorphisms (SNPs) -1237T/C
and 2848A/G in the TLR9 gene were recently linked to CD-
associated variants in CARD15, IL23R, and DLG5, thus dif-
ferentially modulating CD susceptibility.
146 It remains to be
shown whether these SNPs may functionally impair TLR9
sensing of commensal DNA, leading to aggravation of inﬂam-
matory disease through Treg/Teff imbalance in the intestinal
mucosa.
147
In addition, a number of IBD-associated genetic
defects, secondarily inﬂuencing the function and (patho)-
physiology of intestinal TLRs, have been identiﬁed and are
associated with decreased or increased susceptibility to
colitis:
IL-10
IL-10 critically affects interactions between the
microbiota and host defense of the gut in order to maintain
mucosal homeostasis and prevent intestinal inﬂammation.
A balanced microbiota plays an important role in the
mucosal production of antiinﬂammatory IL-10. Commensal
Bacteroides protects from colitis through the induction of
interleukin-10-producing CD4þ T cells.
148 Defects in the
IL-10 gene disturb the bilateral host–symbiont relationship
through alterations of mucosal immune responses, ulti-
mately leading to intestinal inﬂammation. Mice that are de-
ﬁcient in IL-10 develop spontaneous TH1/TH17-driven
enterocolitis,
149,150 which resembles human IBD in many
histopathological and immunological features and which is
dependent on the presence of commensals.
151 Loss-of-func-
tion mutations in the genes encoding the two polypeptide
chains of the IL-10 receptor (IL-10RA or IL-10RB) have
recently been associated with early onset hyperinﬂamma-
tion of the intestine in patients.
152 Furthermore, a polymor-
phism in the IL-10 gene has been associated with increased
risk to develop UC.
153 Collectively, these data imply that
absence of IL-10-mediated antiinﬂammatory immune
responses may play an important role in the pathophysiol-
ogy of human IBD.
The mechanisms by which IL-10 manages intestinal
homeostasis and suppresses inﬂammation are diverse and
include the following: maintaining the mucosal immune
system in a partially unresponsive state and preventing the
development of pathogenic T-cell-mediated responses to
bacteria-speciﬁc antigens,
154,155 sustaining the suppressive
function of (Foxp3þ) Tregs
156 and restricting excessive
immune responses by limiting uncontrolled generation of
TH1/TH17 cells and production of proinﬂammatory cyto-
kines (IFN-c, IL-6, IL-12, IL-17, IL-23) in the lamina prop-
ria.
150,157 Furthermore, IL-10 may negatively regulate cell
signaling via TLR-MyD88 in an autocrine loop. The under-
lying mechanisms are not yet fully understood, but IL-10
may directly dampen MyD88-dependent proinﬂammatory
signaling by ubiquitination and degradation of IRAK4 and
TRAF6.
158 Conversely, absence of MyD88 protects IL-10-
deﬁcient mice against the development of spontaneous
enterocolitis by inhibiting downstream NF-jB-dependent
TH1/TH17 polarization.
159,160 Similarly, commensal-de-
pendent expansion of colitogenic CD4þ TH17 cells is also
impaired in Rag-2 /  mice transferred with MyD88 / 
CD4
þCD45RB
hi cells, resulting in signiﬁcant delay in
onset of spontaneous colitis.
27,28
But our knowledge of how commensal-dependent
TLRs, upstream of MyD88, may differentially regulate the
phenotype of colitis in the IL-10-deﬁcient host remains so
far limited. Dual-association of germ-free IL-10 /  mice
with the nonpathogenic commensal bacteria strains E. coli/
E. faecalis induces severe colitis
155 which is abolished in the
absence of MyD88.
160 Several TLRs (TLR2/3/4/5/9
161,162)
are selectively modulated by E. coli/E. faecalis. Two recent
studies
163,164 showed independently that TLR4 may not be
the culprit in the pathogenesis of commensal-dependent coli-
tis in IL-10 /  mice. On the contrary, the absence of TLR4
leads rather to an increase in intestinal inﬂammation in
IL-10 /  mice with uncontrolled generation of aberrant
IFN-c- and IL-17-producing (Foxp3þ) Tregs and altered
control of IEC turnover.
163 T-cell TLR4 can negatively regu-
late activation signals delivered by the T-cell receptor (TCR)
through TRIF-dependent MKP3 signaling.
164 These ﬁnd-
ings
163,164 imply that essential TLR4 signals from the
commensal microbiota help to limit propagation of colitic
effector CD4þ T cells, and signiﬁcantly ameliorate disease
course in the context of IL-10 deﬁciency.
The contrasting effects of TLR4 and MyD88 in IL-
10 deﬁciency are so far not fully understood. But it must
be considered that TLR4 also signals through the MyD88-
independent pathway via TRIF to induce type I IFN.
165
TLR3/9-mediated production of type I IFN has been shown
to protect against colitis in the IL-10-deﬁcient mice by
negatively regulating TH17 differentiation in the lamina
propria.
166,167 It remains to be investigated whether the
antiinﬂammatory function of TLR4 signaling in the
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It also remains to be resolved whether loss of mucosa-pro-
tective TLR4 leads to altered function of other TLRs (or
PRRs) in the intestinal mucosa, which may be responsible
for exacerbation of colitis in IL-10 deﬁciency. A role of
non-TLR innate recognition cannot be ruled out. Although
MyD88 serves as a scaffold adaptor protein at the cross-
road of many common TLR-dependent signaling pathways,
MyD88 is not TLR-speciﬁc. MyD88 converges with TLR-
independent signaling modules, including focal adhesion
kinase,
168 IL-1R, and IL-18R.
169 Future studies will need
to dissect the mechanistic involvement of other TLRs
(alone and in combination) as well as related innate
immune sensors (NLRs) in commensal-dependent enteroco-
litis in the absence of IL-10. Using TLR ligands or drugs
that selectively induce TRIF or type I IFN in the intestinal
mucosa could have compelling potential to prevent or treat
acute inﬂammatory ﬂares in IBD patients with lack of
IL-10 signaling.
STAT3
However, the outcome of TLR4-mediated innate
immune responses seems to be ambiguous, primarily result-
ing from variable involvement of affected signaling path-
ways and cell populations within the intestinal mucosa,
depending on different IBD genotypes as well as diverse
inﬂuences by the intestinal ecosystem. STAT3 plays a piv-
otal role in the control of innate immunity in the intestine.
The gene region of STAT3 was recently linked to human
IBD.
170 STAT3 is a pleiotropic transcription factor acti-
vated by a variety of mucosa-/cytoprotective cytokines and
growth factors. For instance, IL-22 mediates mucosal resti-
tution of mucus-producing goblet cells via STAT3.
171 Con-
sequently, IEC-speciﬁc deletion of STAT3 leads to
increased susceptibility to acute DSS colitis.
172 Myeloid
cell-speciﬁc deletion of STAT3 results in development of
spontaneous enterocolitis in mice.
173 Strikingly, crossing
myeloid cell-speciﬁc STAT3-deﬁcient mice with TLR4-
knockout attenuates intestinal inﬂammation,
174 implying
that disruption of STAT3 expression leads to overly acti-
vated innate immune responses via TLR4 toward the resi-
dent microﬂora and interferes with the adaptive immune
system by inhibiting induction of antigen-speciﬁc T-cell
tolerance in the intestinal mucosa. In return, defective
T-cell apoptosis may subvert signaling of, e.g., TLR5/9 (or
other PRRs), further mobilizing the effector function of
TH1 cells, leading to enhanced IFNc and IL-12/IL-23 pro-
duction and excessive cell proliferation, which aggravates
and sustains injurious immunologic reactions in the
inﬂamed intestine. Taken together, in the scenario of a
genetic STAT3 defect, targeted inhibition of TLR4 recogni-
tion and signaling may represent a more desirable treat-
ment goal in order to comprehensively abolish climaxed
TH1-dominant inﬂammatory responses that are caused by
long-standing, cell-speciﬁc innate and adaptive immune
alterations to luminal antigens in the lamina propria.
CARD15
CARD15 exerts antibacterial activity through defen-
sins,
175,176 thus critically inﬂuencing the commensal com-
position.
45 Genetic variations of CARD15 have been linked
to increased susceptibility to some types of CD
177,178 and
associated with defensin deﬁciency.
69,179,180 Of note,
CARD15 synergizes with TLRs to trigger TH2-type polar-
ization,
181 contributing to maintenance of TLR-mediated
intestinal homeostasis by downmodulating exaggerated
TH1-responses in the intestinal mucosa. Chronic CARD15
stimulation abrogates TLR-induced proinﬂammatory
immune responses in a cell-type-speciﬁc manner through
IRAK-M.
182 Once TLR-tolerant, macrophages still remain
responsive to stimulation via CARD15.
183 Colonic lamina
propria cells isolated from mice treated with a CARD15
ligand and cultured ex vivo exhibit reduced production of
proinﬂammatory cytokines upon TLR stimulation, while
the presence of a CD-associated CARD15 mutation fails to
block TLR-mediated NF-jB-hypersensitivity in adenoma-
tous polyposis coli (APC).
184,185 Together, these observa-
tions highlight the importance of regulatory networks and
synergy between TLR and CARD15 pathways in sustaining
controlled innate immune responses to maintain normal
mucosal homeostasis. Imbalanced interactions between
CARD15 and TLR pathways could lead to disease by
uncontrolled and excessive actions of the innate immune
system. Genetic defects in CARD15 may lead to changes
in the commensal composition due to defensin deﬁciency,
which may disturb homeostatic TLR signaling, thus pro-
moting inﬂammatory disease.
MDR1a
Several variations of the ABCB1/MDR1 gene have
been associated with increased susceptibility to UC.
186
Mice deﬁcient in MDR1a develop spontaneous chronic
colitis that resembles human UC.
187 Commensal bacteria
drive the inﬂammatory process and changes in the
commensal composition due to lack of the MDR1a trans-
porter have recently been described,
188 but the innate
immune mechanisms functionally involved in modulating
disease have not been well deﬁned yet. CRX-526, a lipid
A-mimetic that acts as a TLR4 inhibitor, blocks LPS-
induced TNF-a, IL-12p70. and IL-6 in DCs and monocytes
in vitro. Systemic administration of CRX-526 has been
shown to effectively inhibit the development of chronic
colitis in MDR1a-deﬁcient mice, implying a potential role
of aberrant TLR4 activation in perpetuating inﬂammatory
responses in the presence of MDR1a defects.
189 However,
recent studies suggest that some lipid A mimetics may also
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effects in vitro.
190 The cellular mechanisms remain to be
resolved in detail how CRX-526 could have exerted its
beneﬁcial effects in vivo. Furthermore, conventional hous-
ing conditions (e.g., Helicobacter bilis) may inﬂuence the
clinical course of colitis in MDR1a-deﬁcient mice.
191,192 It
remains to be directly shown whether selected microbial
species due to changes of the commensal composition may
subvert host immune responses in the context of MDR1a
deﬁciency, thus possibly allowing pathogenic hyperactiva-
tion of TLR4 (and other TLRs).
The pathogenesis of pancolitis in MDR1a /  mice
involves a primary IEC barrier defect associated with alter-
ations in IFNc-responsive genes in the lamina prop-
ria.
187,193 We have previously shown that prophylaxis with
a TLR2 agonist delays spontaneous onset of chronic colitis
in MDR1a-deﬁcient mice raised under speciﬁc-pathogen-
free conditions.
102 Despite the presence of CC-chemokines
and proinﬂammatory IFNc in the mucosal milieu, treatment
with the TLR2 ligand maintained IEC barrier integrity, by
preventing TJ/GJ disruption and associated exaggeration of
inﬂammatory responses in this genetically susceptible
host.
102 These ﬁndings demonstrate that TLR2-mediated
preservation of IEC barrier function not only protects
against acute inﬂammatory stress-induced mucosal damages
but also prevents spontaneous chronic colitis. The continu-
ous presence of the TLR2 agonist by long-term administra-
tion in relatively high concentrations may have elicited
cross-tolerance toward the facultative-pathogenic commen-
sal communities in MDR1a deﬁciency.
13 Future studies
will need to examine whether selective TLR2 activation
may also exert mucosa-protective effects in other murine
models of colitis (such as IL-10 / ; STAT3-mutant). The
contribution of additional antiinﬂammatory responses medi-
ated by TLR2 on lamina propria mononuclear cells must
be elucidated in detail.
194
COLITIS-ASSOCIATED CANCER IN IBD
Commensals may trigger colon tumor formation
through ampliﬁcation of TH17 responses during colitis.
195
Recent studies have highlighted an important role of aber-
rant TLR signaling in promoting colitis-associated cancer.
TLRs are expressed on colon cancer cells and neighboring
cells in the microenvironment. Studies using chemically
induced colon carcinogenesis in chronic DSS colitis dem-
onstrate that hyperproliferative TLR signals may inﬂuence
the course of inﬂammation-associated colorectal cancer.
TLR4 signaling on IEC is necessary for recruitment and
activation of Cox-2-expressing macrophages that promote
colorectal tumor growth through PGE2.
196 TLR4-deﬁcient
mice which fail to produce PGE2 are protected from
colon cancer in this model,
197 whereas mice deﬁcient in
SIGIRR, a negative regulator for TLR4 signaling, demon-
strate increased susceptibility.
77,78 However, while TLR4
activation promotes proliferative tumor-responses in IEC, it
may induce antitumor responses in cytotoxic T cells.
198
This ﬁnding implies an ambiguous role of TLR4 in tumor
development, depending on the predominant cell types
involved.
It remains unclear how innate immune dysfunction con-
tributes to tumor development through impairment of cancer
cell stem cell differentiation and survival via the Wnt-APC-b-
catenin cascade. A possible indirect link between MyD88 and
the tumor suppressor gene APC has recently been reported.
199
MyD88 null mice that also carry a germline mutation in the
APC gene exhibited regression of spontaneous development
of pretumoric adenomas, however, predominantly in the small
intestine, which argues against a primary role of TLR signal-
ing in the Apc
Min/þ tumor model, as the bacterial load is nor-
mally very low in this part of the gastrointestinal tract. Of
note, MyD88 / /Apc
Min/þ mice exhibited increased IEC
apoptosis and it is possible that deﬁciency of MyD88
impaired stability of its death domain-partner FADD to
enhance recruitment of caspase 8, promoting IEC turnover
and delaying tumor progression.
It will be important to examine how aberrant modula-
tion of TLRs contributes to initiation and progression of
colitis-associated neoplasia in the context of IBD-
TABLE 1. Toll-like Receptors (TLRs)
TLR structure and signaling
l 13 mammalian, type I transmembrane glycoreceptors (10 in
humans; 12 in mice) with divergent LRR-ectodomain and
conserved intracellular TIR domain
l recognition of alarm patterns or signals:
a) microbiota/viral-associated (commensal/pathogen)
b) damage-associated (endogenous/exogenous)
l downstream activation of pro-/antiinﬂammatory cytokines
and chemokines and link to adaptive immunity through at
least 5 different adaptor proteins
Regulatory dichotomy in TLR expression and function
between health and IBD
l constitutively or inducibly expressed throughout the whole
GI tract by a wide variety of cell types, including IEC
lineages, myoﬁbroblasts, monocytes/macrophages, DCs and
T cells
l healthy intestine:
a) TLRs are present only in small amounts
b) negative regulators maintain basal state of activation and
prevent prolonged and excessive TLR signaling
l diseased intestine:
a) distinct TLRs are signiﬁcantly upregulated in certain cell
subsets in intestinal mucosa
b) positive regulators initiate aberrant state of activation and
allow uncontrolled TLR signaling
See text for details and references.
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previously proposed that absence of TLR4 drives aggres-
sive development of spontaneous colitis-associated adeno-
carcinoma in IL-10 /  mice,
200 but detailed investigations
of the underlying mechanisms are so far lacking. Dissect-
ing the direct and indirect interactions between components
of the ‘‘environment-genetics-immunity’’-triad and TLRs
that trigger cancer pathogenesis in human IBD may help to
develop novel immunomodulators that mediate effective
cytotoxicity in cancer cells only and induce distinct antitu-
mor responses in the microenvironment of the intestinal
mucosa.
CONCLUSIONS
An important role for TLR signaling (summary in
Table 1) in the pathogenesis of IBD has been established
through many studies over the last decade. The impact of
TLR signaling on commensal–host interactions appears to
be context-dependent. Environment, genetics, and host
immunity modulate TLRs in the intestinal mucosa (Fig. 1).
Conversely, mucosal TLR signaling inﬂuences outcome of
environmental signals, genetic functions, and immune
responses in the intestine. There is an important dichotomy
in TLR regulation and function between healthy and
inﬂamed intestinal mucosa, reﬂecting a ﬁne line between
host protection and destruction. In the healthy host, basal
TLR signaling is signiﬁcantly involved in protective host
defense and tissue repair responses, crucially maintaining
mucosal and commensal homeostasis. In the IBD-suscepti-
ble host, aberrant TLR signaling may contribute to destruc-
tive host responses and chronic inﬂammation, disturbing
mucosal and commensal homeostasis and leading to many
different clinical phenotypes (summary in Table 2). Hyper-
activation of the adaptive immune system, secondary to
TLR deﬁciency, may drive tissue damage and progressive
inﬂammation in IBD. Characterization of different IBD-
associated gene defects have highlighted fundamental,
deﬁning variability in TLR regulation and function,
dependent on disease processes and predominant cell
type involvement in the intestinal mucosa (summary in
Table 3). Further advances in our mechanistic understand-
ing of this multilayered interplay (Fig. 1) between compo-
nents of the ‘‘environment-genetics-immunity’’ triad and
TLRs (and other PRRs) will be central to future progress
in 1) elucidating geno-/phenotype correlations in the patho-
genesis of IBD and colitis-associated colorectal cancer, and
2) identifying novel approaches that may exploit innate
immune functions as a means to prevent and/or treat IBD
and related systemic manifestations.
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